Study of the Therapeutic Vaccine (ISA101) to Treat Advanced or Recurrent Cervical Cancer (CervISA)
Read time: 1 mins
Last updated:18th Apr 2014
The purpose of the study is to assess the safety, tolerability and to assess the HPV-specific immune responses of different doses of ISA101 vaccine with or without pegylated IFNα as combination therapy with carboplatin and paclitaxel.
|Study start date||2014-04-18|